{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/wst-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/wst-stock-analysis/data.json",
 "title": "West (WST) Stock Forecast & Price Target (2026)",
 "description": "West Pharmaceutical Services Inc. (WST) stock: Healthcare, Medical Instruments & Supplies. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "West Pharmaceutical Services Inc. (WST)",
 "published": "2026-07-24T09:34:11+00:00",
 "modified": "2026-09-27T13:58:43.179+00:00",
 "generated": "2026-09-27T16:50:33.668Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "WST",
  "name": "West Pharmaceutical Services Inc.",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Medical Instruments & Supplies",
  "country": "United States",
  "website": "https://www.westpharma.com"
 },
 "quote": {
  "price": 370.44,
  "previousClose": 373.6,
  "change": -3.16,
  "changePercent": -0.85,
  "open": 372.01001,
  "high": 372.14001,
  "low": 368.45001,
  "volume": 434000,
  "averageVolume": 742340,
  "marketCap": 26069997275,
  "fiftyTwoWeekHigh": 386,
  "fiftyTwoWeekLow": 223.83,
  "marketOpen": false,
  "asOf": "2026-09-27T13:58:43.000Z"
 },
 "statistics": {
  "pe": 46.950573,
  "eps": 7.89,
  "dividendYield": 0.0023759381942835447,
  "beta": 1.135,
  "priceToSales": 7.836359,
  "priceToBook": 8.721571,
  "revenueTtm": 3326799872,
  "grossMargin": 0.3773930987045741,
  "returnOnEquity": 0.19087
 },
 "technicals": {
  "rsi": 74.18,
  "macd": 6.86,
  "sma50": 350.44,
  "sma200": 299.78,
  "rsiSignal": "Overbought",
  "trend": "Bullish",
  "pricePosition": "Bullish",
  "macdSignal": "Bullish",
  "rating": "Bullish"
 },
 "analysis": {
  "rating": "Buy",
  "score": 76,
  "consensus": "Buy",
  "fairValue": 410,
  "analystTarget": 410,
  "analystCount": 17,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-27T13:58:43.000Z",
  "priceAtAnalysis": 370.44,
  "volatility": {
   "daily": 1.3,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bullish",
  "conservativeEntry": 363.03,
  "aggressiveEntry": 370.44,
  "stopLoss": 349.96,
  "stopLossPercent": 3.6,
  "targets": [
   381.18,
   399.33,
   417.49
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 262.41,
    "base": 414.66,
    "upside90th": 655.24
   },
   {
    "year": 2028,
    "downside10th": 243.02,
    "base": 464.15,
    "upside90th": 886.51
   },
   {
    "year": 2029,
    "downside10th": 235.21,
    "base": 519.56,
    "upside90th": 1147.67
   },
   {
    "year": 2030,
    "downside10th": 232.91,
    "base": 581.58,
    "upside90th": 1452.22
   },
   {
    "year": 2031,
    "downside10th": 234.01,
    "base": 651,
    "upside90th": 1810.98
   },
   {
    "year": 2032,
    "downside10th": 237.58,
    "base": 728.7,
    "upside90th": 2235.09
   },
   {
    "year": 2033,
    "downside10th": 243.1,
    "base": 815.68,
    "upside90th": 2736.95
   },
   {
    "year": 2034,
    "downside10th": 250.29,
    "base": 913.05,
    "upside90th": 3330.73
   },
   {
    "year": 2035,
    "downside10th": 259.02,
    "base": 1022.04,
    "upside90th": 4032.79
   },
   {
    "year": 2036,
    "downside10th": 269.19,
    "base": 1144.03,
    "upside90th": 4862.1
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "WST Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$372.01",
    "Day Range": "$368.45 to $372.14",
    "Prev Close": "$373.60",
    "Volume": "434.0K",
    "52-Week Range": "$223.83 to $386.00",
    "Market Cap": "$26.07B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a significant premium to sector peers (+47%), suggesting market expectations for superior growth or market position."
   ]
  },
  {
   "id": "financials",
   "title": "WST Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, WST beat estimates 4 times. However, the stock fell 3 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "WST Analysis",
   "text": [
    "West Pharmaceutical Services Inc. (WST) is trading above its 50-day and 200-day moving averages ($350.44 and $299.78), signaling an uptrend. The 50-day SMA is at $350.44 and the 200-day SMA is at $299.78, with the current price of $370.44 comfortably positioned above both. The Relative Strength Index (RSI) is currently at 74.18, indicating overbought conditions and a potential for a short-term correction. The Moving Average Convergence Divergence (MACD) is positive at 6.86, supporting the bullish momentum. Key support levels are identified around the 50-day SMA at $350.44 and the 200-day SMA at $299.78. Resistance is less clearly defined given the upward trend, but previous price action suggests psychological levels may emerge. Volume on the latest trading day was 434,000, which is below the average volume of 742,340, suggesting a slight decrease in trading activity as the stock approaches overbought territory. The overall chart structure indicates a strong bullish trend, but the overbought RSI warrants monitoring for potential consolidation or a minor pullback.",
    "WST has a track record of exceeding analyst EPS estimates, demonstrating strong operational execution and financial discipline.",
    "The company's ROE of 19.09% significantly outperforms the sector average, indicating efficient capital utilization and profitability.",
    "The RSI is at 74.18, signaling that the stock may be overextended and due for a short-term correction or consolidation.",
    "Insiders have sold $6.6 million worth of stock across 42 transactions, indicating a moderate sell signal that warrants attention.",
    "WST trades at higher P/E and P/S ratios than its sector peers, suggesting that its current price may already reflect significant growth expectations.",
    "The base case scenario for West Pharmaceutical Services Inc. (WST) over the next 6-12 months anticipates continued growth, supported by analyst price targets averaging $405.375 and a median target of $410. The company's strong ROE of 19.09% and consistent earnings beats suggest it can maintain its premium valuation. Forward-looking revenue growth estimates for the current year are around 10.00%, with next year projected at 6.00%, indicating sustained business expansion. Potential upside catalysts include further market share gains in its specialized medical device segment and successful new product introductions. Conversely, downside risks involve the stock's current overbought technical condition (RSI 74.18) which could trigger a short-term correction, and the higher valuation multiples compared to sector averages. Any significant slowdown in revenue growth or unexpected competitive pressures could also impact the stock's performance."
   ],
   "lists": {
    "ProTips": [
     "Monitor the RSI for WST, which is currently overbought at 74.18, for signs of a potential pullback or consolidation.",
     "Given the moderate insider selling signal, keep an eye on future insider transactions for any changes in sentiment.",
     "The company pays a dividend of $0.88 annually, yielding approximately 0.24% at the current price, which may appeal to income-focused investors."
    ]
   },
   "catalysts": [
    {
     "type": "Bullish",
     "title": "Consistent Earnings Beats",
     "text": "WST has a track record of exceeding analyst EPS estimates, demonstrating strong operational execution and financial discipline.",
     "source": "Earnings Reports"
    },
    {
     "type": "Bullish",
     "title": "Strong Return on Equity",
     "text": "The company's ROE of 19.09% significantly outperforms the sector average, indicating efficient capital utilization and profitability.",
     "source": "Company Fundamentals"
    },
    {
     "type": "Bearish",
     "title": "Overbought Technical Conditions",
     "text": "The RSI is at 74.18, signaling that the stock may be overextended and due for a short-term correction or consolidation.",
     "source": "Technical Analysis"
    },
    {
     "type": "Bearish",
     "title": "Moderate Insider Selling",
     "text": "Insiders have sold $6.6 million worth of stock across 42 transactions, indicating a moderate sell signal that warrants attention.",
     "source": "Insider Transactions"
    },
    {
     "type": "Neutral",
     "title": "Premium Valuation Multiples",
     "text": "WST trades at higher P/E and P/S ratios than its sector peers, suggesting that its current price may already reflect significant growth expectations.",
     "source": "Fundamental Analysis"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "West Pharmaceutical Services Inc. (WST) exhibits strong fundamental characteristics with a current P/E ratio of 46.95, which is higher than the sector median of 31.9, suggesting a premium valuation. However, its Price-to-Sales ratio of 7.84 is also above the sector median of 3.7, reinforcing the premium. The company's Return on Equity (ROE) stands at a strong 19.09%, significantly outperforming the sector average of 6.9%. Its Net Profit Margin is healthy at 16.98%, and the Debt-to-Equity ratio is a low 0.11, indicating a strong balance sheet. Despite the higher valuation multiples, WST's superior profitability and efficient capital utilization justify some of this premium. The company's ability to generate strong returns on equity and maintain healthy profit margins, coupled with a conservative debt level, provides a solid foundation. While investors should be mindful of the current valuation, the underlying financial strength and operational efficiency suggest that the premium may be warranted by the company's performance and growth prospects.",
    "West Pharmaceutical Services Inc. (WST) demonstrated strong earnings performance in its most recent reported quarters. For the quarter ending June 2026, the company reported an EPS of $2.37, beating the estimate of $2.08 by 13.94%, although the stock experienced a price decline of -7.67% on the announcement. Prior quarters also showed consistent earnings beats, with the quarter ending March 2026 showing a 26.79% surprise and the quarter ending December 2025 a 11.48% surprise. This pattern of exceeding analyst expectations highlights the company's operational execution and ability to deliver on financial targets.",
    "The primary risk for West Pharmaceutical Services Inc. (WST) is its current valuation, with a P/E ratio of 46.95 and a Price-to-Sales ratio of 7.84, both exceeding sector medians. The stock's RSI is in overbought territory at 74.18, indicating potential for a short-term pullback. Additionally, insider activity shows a moderate sell signal, with $6.6 million in net sales across 42 transactions, which warrants monitoring for any sustained trend."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "26.07B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "46.95"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "7.89"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.24%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "386.00"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "223.83"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bullish RSI Overbought SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($350.44) above the 200-day SMA ($299.78), price action is firmly bullish above key moving averages, RSI at 74.2 indicates overbought conditions; consider caution for immediate entries."
   ],
   "facts": {
    "RSI": "Overbought",
    "SMA Cross": "Bullish",
    "Price vs SMA": "Bullish",
    "MACD": "Bullish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "74.18"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "6.86"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "350.44"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "299.78"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.16",
    "Correlation with Nasdaq 100 (QQQ)": "+0.13",
    "Correlation with Bitcoin (BTC)": "+0.09",
    "Correlation with Gold (XAU)": "+0.01"
   }
  },
  {
   "id": "trade-plans",
   "title": "WST Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for pullback",
    "Higher risk, immediate entry",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (74.2) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$381.18",
    "TARGET 2": "$399.33",
    "TARGET 3": "$417.49",
    "STOP LOSS": "$349.96"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+1.74%",
    "Average Feb return": "-4.01%",
    "Average Mar return": "+2.53%",
    "Average Apr return": "+5.20%",
    "Average May return": "+1.28%",
    "Average Jun return": "+5.23%",
    "Average Jul return": "+5.33%",
    "Average Aug return": "+2.44%",
    "Average Sep return": "-2.19%",
    "Average Oct return": "-2.03%",
    "Average Nov return": "+3.11%",
    "Average Dec return": "+0.61%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.30%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in WST in September 2016 would be worth about $50,393 today, compared with about $35,782 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in WST today could grow to about $30,883 by 2036 in the base case, with a bull case near $131,252 and a bear case around $7,267. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "WST Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $582 for WST by 2030 in the base case, from $370 today (1.6x over 4 years). The downside path ends near $233. These are outcomes of a Monte Carlo simulation run on WST's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using WST's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "WST simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$262",
        "$415",
        "$655"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$243",
        "$464",
        "$887"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$235",
        "$520",
        "$1,148"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$233",
        "$582",
        "$1,452"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$234",
        "$651",
        "$1,811"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$238",
        "$729",
        "$2,235"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$243",
        "$816",
        "$2,737"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$250",
        "$913",
        "$3,331"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$259",
        "$1,022",
        "$4,033"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$269",
        "$1,144",
        "$4,862"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "RMD ResMed Inc. NYSE $222.00 +0.05%",
     "url": "https://clearank.com/stock/rmd-stock-analysis/"
    },
    {
     "text": "AGL agilon health, Inc. NYSE $80.73 +6.46%",
     "url": "https://clearank.com/stock/agl-stock-analysis/"
    },
    {
     "text": "ABBV AbbVie Inc. NYSE $264.34 -0.29%",
     "url": "https://clearank.com/stock/abbvie-abbv/"
    },
    {
     "text": "SYK Stryker Corp. NYSE $272.36 +0.97%",
     "url": "https://clearank.com/stock/stryker-syk/"
    },
    {
     "text": "MRK Merck & Co., Inc. NYSE $148.78 +0.54%",
     "url": "https://clearank.com/stock/merck-mrk/"
    },
    {
     "text": "HCA HCA Healthcare, Inc. NYSE $435.61 +2.86%",
     "url": "https://clearank.com/stock/hca-healthcare-hca/"
    },
    {
     "text": "TMO Thermo Fisher Scientific Inc. NYSE $675.00 -0.50%",
     "url": "https://clearank.com/stock/tmo-stock-analysis/"
    },
    {
     "text": "VKTX Viking Therapeutics, Inc. NASDAQ $35.56 -3.24%",
     "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "VUG vs SCHG Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/vug-vs-schg/"
    },
    {
     "text": "VOO vs SCHG Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/voo-vs-schg/"
    },
    {
     "text": "SLV vs PSLV Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/slv-vs-pslv/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "WST Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$6.6M",
    "Insiders": "18",
    "Avg Transaction": "$1.6M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in WST",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "May 7, 2024",
       "cells": [
        "GREEN ERIC MARK Chief Executive Officer",
        "Sell",
        "66.0K",
        "$24.2M"
       ]
      },
      {
       "label": "Feb 27, 2024",
       "cells": [
        "GREEN ERIC MARK Chief Executive Officer",
        "Sell",
        "64.1K",
        "$23.1M"
       ]
      },
      {
       "label": "Aug 8, 2023",
       "cells": [
        "GREEN ERIC MARK Chief Executive Officer",
        "Sell",
        "44.0K",
        "$17.4M"
       ]
      },
      {
       "label": "May 9, 2023",
       "cells": [
        "GREEN ERIC MARK Chief Executive Officer",
        "Sell",
        "44.0K",
        "$16.0M"
       ]
      },
      {
       "label": "Mar 7, 2023",
       "cells": [
        "GREEN ERIC MARK Chief Executive Officer",
        "Sell",
        "44.0K",
        "$14.2M"
       ]
      },
      {
       "label": "Dec 5, 2022",
       "cells": [
        "GREEN ERIC MARK Chief Executive Officer",
        "Sell",
        "44.0K",
        "$10.5M"
       ]
      },
      {
       "label": "Aug 6, 2024",
       "cells": [
        "GREEN ERIC MARK Chief Executive Officer",
        "Sell",
        "30.7K",
        "$9.4M"
       ]
      },
      {
       "label": "Aug 11, 2023",
       "cells": [
        "LAI QUINTIN J. PH.D. Officer",
        "Sell",
        "21.1K",
        "$8.3M"
       ]
      },
      {
       "label": "Aug 2, 2023",
       "cells": [
        "BIRKETT BERNARD JOHN Officer",
        "Sell",
        "22.3K",
        "$8.3M"
       ]
      },
      {
       "label": "May 18, 2017",
       "cells": [
        "FEDERICI WILLIAM J Chief Financial Officer",
        "Sell",
        "55.0K",
        "$5.2M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=West+Pharmaceutical+Services+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is West Pharmaceutical Services Inc.'s stock price forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, West Pharmaceutical Services Inc.'s (WST) stock price is projected to reach a base case of $581.58 by 2030. The downside projection is $232.91, while the upside projection is $1452.22. These figures represent statistical simulation outcomes, not guaranteed price targets."
  },
  {
   "question": "Is West Pharmaceutical Services Inc. stock a buy right now?",
   "answer": "West Pharmaceutical Services Inc. (WST) is currently rated a Buy with a consensus score of 76. Analysts have a median price target of $410, suggesting a 10.7% upside from the current price of $370.44. The stock is trading above key moving averages, indicating positive momentum, though it is in overbought territory."
  },
  {
   "question": "What are the key technical indicators for WST stock?",
   "answer": "WST is trading above its 50-day and 200-day moving averages ($350.44 and $299.78), indicating an uptrend. The RSI is at 74.18, signaling overbought conditions, while the MACD is positive at 6.86, suggesting bullish momentum."
  },
  {
   "question": "How does WST's valuation compare to its sector peers?",
   "answer": "WST's P/E ratio of 46.95 and P/S ratio of 7.84 are higher than the sector medians of 31.9 and 3.7, respectively. However, its ROE of 19.09% significantly outperforms the sector average of 6.9%."
  },
  {
   "question": "What was West Pharmaceutical Services Inc.'s recent earnings performance?",
   "answer": "In the quarter to June 2026, WST reported an EPS of $2.37, exceeding estimates by 13.94%. The company has a history of consistent earnings beats, demonstrating strong operational execution."
  },
  {
   "question": "Are insiders buying or selling West Pharmaceutical Services Inc. stock?",
   "answer": "Insiders are net sellers of WST stock, with $6.6 million in total sales in recent filings and no reported purchases. This indicates a moderate sell signal, which investors should monitor."
  },
  {
   "question": "What is the outlook for West Pharmaceutical Services Inc. over the next 6-12 months?",
   "answer": "The outlook for WST is positive, with analysts projecting a median price target of $410. The company is expected to continue its growth trajectory, supported by strong fundamentals and consistent earnings performance, though near-term technical overbought conditions may lead to consolidation."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "RMD",
    "name": "ResMed Inc. NYSE",
    "price": "$222.00",
    "change": "+0.05%",
    "url": "https://clearank.com/stock/rmd-stock-analysis/"
   },
   {
    "ticker": "AGL",
    "name": "agilon health, Inc. NYSE",
    "price": "$80.73",
    "change": "+6.46%",
    "url": "https://clearank.com/stock/agl-stock-analysis/"
   },
   {
    "ticker": "ABBV",
    "name": "AbbVie Inc. NYSE",
    "price": "$264.34",
    "change": "-0.29%",
    "url": "https://clearank.com/stock/abbvie-abbv/"
   },
   {
    "ticker": "SYK",
    "name": "Stryker Corp. NYSE",
    "price": "$272.36",
    "change": "+0.97%",
    "url": "https://clearank.com/stock/stryker-syk/"
   },
   {
    "ticker": "MRK",
    "name": "Merck & Co., Inc. NYSE",
    "price": "$148.78",
    "change": "+0.54%",
    "url": "https://clearank.com/stock/merck-mrk/"
   },
   {
    "ticker": "HCA",
    "name": "HCA Healthcare, Inc. NYSE",
    "price": "$435.61",
    "change": "+2.86%",
    "url": "https://clearank.com/stock/hca-healthcare-hca/"
   },
   {
    "ticker": "TMO",
    "name": "Thermo Fisher Scientific Inc. NYSE",
    "price": "$675.00",
    "change": "-0.50%",
    "url": "https://clearank.com/stock/tmo-stock-analysis/"
   },
   {
    "ticker": "VKTX",
    "name": "Viking Therapeutics, Inc. NASDAQ",
    "price": "$35.56",
    "change": "-3.24%",
    "url": "https://clearank.com/stock/viking-therapeutics-vktx/"
   }
  ],
  "comparisons": [
   {
    "ticker": "VUG vs SCHG Comparison",
    "name": "",
    "url": "https://clearank.com/compare/vug-vs-schg/"
   },
   {
    "ticker": "VOO vs SCHG Comparison",
    "name": "",
    "url": "https://clearank.com/compare/voo-vs-schg/"
   },
   {
    "ticker": "SLV vs PSLV Comparison",
    "name": "",
    "url": "https://clearank.com/compare/slv-vs-pslv/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "EIS",
    "text": "iShares MSCI Israel ETF",
    "url": "https://clearank.com/etf/eis-etf-analysis/"
   },
   {
    "ticker": "GWRE",
    "text": "Guidewire Software Inc.",
    "url": "https://clearank.com/stock/gwre-stock-analysis/"
   },
   {
    "ticker": "ROST",
    "text": "Ross Stores Inc.",
    "url": "https://clearank.com/stock/rost-stock-analysis/"
   },
   {
    "ticker": "LUGDF",
    "text": "Lundin Gold Inc",
    "url": "https://clearank.com/stock/lugdf-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "TWLO",
    "text": "↓ 7.96%",
    "url": "https://clearank.com/stock/twlo-stock-analysis/"
   },
   {
    "ticker": "CRDO",
    "text": "↑ 7.65%",
    "url": "https://clearank.com/stock/credo-crdo/"
   },
   {
    "ticker": "BLNE",
    "text": "↓ 7.40%",
    "url": "https://clearank.com/stock/blne-beeline-holdings/"
   },
   {
    "ticker": "GRT/USD",
    "text": "↑ 20.82%",
    "url": "https://clearank.com/crypto/the-graph-grt/"
   },
   {
    "ticker": "SEI/USD",
    "text": "↑ 19.29%",
    "url": "https://clearank.com/crypto/sei-sei/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "BDX",
    "text": "Becton, Dickinson and Company",
    "url": "https://clearank.com/stock/bdx-stock-analysis/"
   },
   {
    "ticker": "ISRG",
    "text": "Intuitive Surgical",
    "url": "https://clearank.com/stock/intuitive-surgical-isrg/"
   },
   {
    "ticker": "RMD",
    "text": "ResMed",
    "url": "https://clearank.com/stock/rmd-stock-analysis/"
   },
   {
    "ticker": "VRTX",
    "text": "Vertex Pharmaceuticals",
    "url": "https://clearank.com/stock/vertex-vrtx/"
   },
   {
    "ticker": "XLV",
    "text": "Health Care Select Sector SPDR",
    "url": "https://clearank.com/etf/health-care-select-spdr-xlv/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/WST-west-pharmaceutical-services-analysis-2026-07.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/WST-west-pharmaceutical-services-analysis-2026-07.png",
     "width": "1280",
     "height": "720",
     "caption": "West Pharmaceutical Services (WST) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/wst-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/wst-stock-analysis/",
        "name": "West (WST) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/wst-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/wst-stock-analysis/",
     "name": "West (WST) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-24T09:34:11+00:00",
     "dateModified": "2026-09-27T13:58:43+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/WST-west-pharmaceutical-services-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/wst-stock-analysis/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/wst-stock-analysis/#richSnippet",
     "headline": "West (WST) Stock Forecast & Price Target (2026)",
     "name": "West (WST) Stock Forecast & Price Target (2026)",
     "description": "West Pharmaceutical Services Inc. (WST) stock: Healthcare, Medical Instruments & Supplies. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-24T09:34:11+00:00",
     "dateModified": "2026-09-27T13:58:43+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "West Pharmaceutical Services Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "WST"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "West Pharmaceutical Services Inc. is a healthcare products manufacturer focused on the design, development, and production of containment and delivery systems for injectable drugs and other healthcare products. The company supplies critical components such as stoppers, seals, syringe and cartridge p",
      "tickerSymbol": "WST",
      "sameAs": "https://www.westpharma.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/wst-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/WST-west-pharmaceutical-services-analysis-2026-07.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/wst-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is West Pharmaceutical Services Inc.'s stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, West Pharmaceutical Services Inc.'s (WST) stock price is projected to reach a base case of $581.58 by 2030. The downside projection is $232.91, while the upside projection is $1452.22. These figures represent statistical simulation outcomes, not guaranteed price targets."
     }
    },
    {
     "@type": "Question",
     "name": "Is West Pharmaceutical Services Inc. stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "West Pharmaceutical Services Inc. (WST) is currently rated a Buy with a consensus score of 76. Analysts have a median price target of $410, suggesting a 10.7% upside from the current price of $370.44. The stock is trading above key moving averages, indicating positive momentum, though it is in overbought territory."
     }
    },
    {
     "@type": "Question",
     "name": "What are the key technical indicators for WST stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "WST is trading above its 50-day ($350.44) and 200-day ($299.78) SMAs, indicating an uptrend. The RSI is at 74.18, signaling overbought conditions, while the MACD is positive at 6.86, suggesting bullish momentum."
     }
    },
    {
     "@type": "Question",
     "name": "How does WST's valuation compare to its sector peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "WST's P/E ratio of 46.95 and P/S ratio of 7.84 are higher than the sector medians of 31.9 and 3.7, respectively. However, its ROE of 19.09% significantly outperforms the sector average of 6.9%."
     }
    },
    {
     "@type": "Question",
     "name": "What was West Pharmaceutical Services Inc.'s recent earnings performance?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "In the quarter to June 2026, WST reported an EPS of $2.37, exceeding estimates by 13.94%. The company has a history of consistent earnings beats, demonstrating strong operational execution."
     }
    },
    {
     "@type": "Question",
     "name": "Are insiders buying or selling West Pharmaceutical Services Inc. stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Insiders are net sellers of WST stock, with $6.6 million in total sales across 42 transactions and no reported purchases. This indicates a moderate sell signal, which investors should monitor."
     }
    },
    {
     "@type": "Question",
     "name": "What is the outlook for West Pharmaceutical Services Inc. over the next 6-12 months?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The outlook for WST is positive, with analysts projecting a median price target of $410. The company is expected to continue its growth trajectory, supported by strong fundamentals and consistent earnings performance, though near-term technical overbought conditions may lead to consolidation."
     }
    }
   ]
  }
 ]
}